文献速递心律失常

无症状与有症状房颤患者早期节律控制的系统分析:EAST-AFNET 4 试验

Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial.
PubMed 文献 · Eur Heart J · 2022-01-01

EAST-AFNET 4 预设分析比较无症状(EHRA I)与有症状房颤患者接受早期节律控制的效果。无症状患者占 30.4%(801/2633),主要复合终点在早期节律控制组与常规治疗组的发生风险比为 0.76(95%CI 0.6–1.03),与有症状患者几乎一致;24 个月症状状态变化在随机组间无差异(P=0.19)。结论认为早期系统节律控制的临床获益在无症状与有症状患者间无差异。

要点

  • 无症状房颤患者占 EAST-AFNET 4 总人群的 30.4%(801/2633)。
  • 无症状患者早期节律控制的主要终点 HR 为 0.76(95%CI 0.6–1.03)。
  • 24 个月症状状态变化在随机组间无差异(P=0.19)。

核心结论

  • 早期系统节律控制的临床获益在无症状与有症状房颤患者间无差异。
  • 结果支持对所有近期诊断房颤且合并心血管疾病的患者共同决策讨论节律控制治疗。

研究设计与样本

  • EAST-AFNET 4 试验的预设分析,比较无症状(EHRA I)与有症状患者的早期节律控制效果。
  • 基线无症状患者 801/2633(30.4%),平均年龄 71.3 岁,女性 37.5%,平均 CHA2DS2-VASc 评分 3.4,心力衰竭 169/801(21.1%)。

主要发现

  • 无症状患者随机至早期节律控制组 395/801,24 个月房颤消融比例 75/395(19.0%),有症状患者为 176/910(19.3%),P=0.672。
  • 主要终点在无症状早期节律控制组发生 79/395,常规治疗组 97/406,HR 0.76(95%CI 0.6–1.03),与有症状患者几乎一致。
  • 24 个月随访时症状状态变化在随机组间无差异(P=0.19)。

临床怎么用

  • 对近期诊断房颤且合并心血管疾病的患者,无论有无症状,均应共同决策讨论早期节律控制治疗的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Clinical practice guidelines restrict rhythm control therapy to patients with symptomatic atrial fibrillation (AF). The EAST-AFNET 4 trial demonstrated that early, systematic rhythm control improves clinical outcomes compared to symptom-directed rhythm control. METHODS AND RESULTS: This prespecified EAST-AFNET 4 analysis compared the effect of early rhythm control therapy in asymptomatic patients (EHRA score I) to symptomatic patients. Primary outcome was a composite of death from cardiovascular causes, stroke, or hospitalization with worsening of heart failure or acute coronary syndrome, analyzed in a time-to-event analysis. At baseline, 801/2633 (30.4%) patients were asymptomatic [mean age 71.3 years, 37.5% women, mean CHA2DS2-VASc score 3.4, 169/801 (21.1%) heart failure]. Asymptomatic patients randomized to early rhythm control (395/801) received similar rhythm control therapies compared to symptomatic patients [e.g. AF ablation at 24 months: 75/395 (19.0%) in asymptomatic; 176/910 (19.3%) symptomatic patients, P = 0.672]. Anticoagulation and treatment of concomitant cardiovascular conditions was not different between symptomatic and asymptomatic patients. The primary outcome occurred in 79/395 asymptomatic patients randomized to early rhythm control and in 97/406 patients randomized to usual care (hazard ratio 0.76, 95% confidence interval [0.6; 1.03]), almost identical to symptomatic patients. At 24 months follow-up, change in symptom status was not different between randomized groups (P = 0.19). CONCLUSION: The clinical benefit of early, systematic rhythm control was not different between asymptomatic and symptomatic patients in EAST-AFNET 4. These results call for a shared decision discussing the benefits of rhythm control therapy in all patients with recently diagnosed AF and concomitant cardiovascular conditions (EAST-AFNET 4; ISRCTN04708680; NCT01288352; EudraCT2010-021258-20).

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Willems S, Borof K, Brandes A, et al. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J. 2022. PMID: 34447995. doi:10.1093/eurheartj/ehab593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。